That's the 1.5 billion dollar question isn't it fuzzyjr. From my recollection of the conversation at the RVX AGM it seems to be numbers patients needed. Of all of the trials in progress,my recollection is that 3 of them have ORRs above 30% but all had low numbers of patients. My guess, and it's only a guess is that any potential deal maker wants to see greater numbers of patients in those trials than the numbers that they are currently seeing. As an example the nut midline trial in the last update showed 8? patients. They had around 50% ORR but a very small number of patients. A potential deal maker may want to see 20 or 30 patients and continue to see 30%+ ORR before cracking that cheque we're all waiting to see.

Just my guess.

tada